866-997-4948(US-Canada Toll Free)

Neuroblastoma - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 506 Pages

Neuroblastoma - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H2 2017, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 27, 20, 1, 48, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 13 and 3 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Neuroblastoma - Overview 10
Neuroblastoma - Therapeutics Development 11
Pipeline Overview 11
Pipeline by Companies 12
Pipeline by Universities/Institutes 17
Products under Development by Companies 20
Products under Development by Universities/Institutes 26
Neuroblastoma - Therapeutics Assessment 28
Assessment by Target 28
Assessment by Mechanism of Action 34
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Neuroblastoma - Companies Involved in Therapeutics Development 43
Ability Pharmaceuticals SL 43
Actuate Therapeutics Inc 43
Advanced Accelerator Applications SA 43
Alissa Pharma 44
Ampio Pharmaceuticals Inc 44
APAvadis Biotechnologies Srl 45
APEIRON Biologics AG 45
AstraZeneca Plc 45
Autolus Ltd 46
Bayer AG 46
Bellicum Pharmaceuticals Inc 47
Bexion Pharmaceuticals LLC 47
BioLineRx Ltd 48
Biotec Pharmacon ASA 48
Boehringer Ingelheim GmbH 49
Bristol-Myers Squibb Co 49
Cancer Prevention Pharmaceuticals Inc 49
Cebiotex SL 50
Celgene Corp 50
Celldex Therapeutics Inc 51
Cielo Therapeutics Inc 51
Cleveland BioLabs Inc 52
CorMedix Inc 52
Curis Inc 53
Cyclacel Pharmaceuticals Inc 53
DEKK-TEC Inc 54
EnGeneIC Ltd 54
Epizyme Inc 54
Errant Gene Therapeutics LLC 55
F. Hoffmann-La Roche Ltd 55
GlaxoSmithKline Plc 56
Green Cross Cell Corp 56
Ignyta Inc 57
Ipsen SA 57
Juno Therapeutics Inc 58
Lindis Biotech GmbH 58
Loxo Oncology Inc 59
MabVax Therapeutics Holdings Inc 59
MacroGenics Inc 59
MediaPharma SRL 60
Merck & Co Inc 60
Morphogenesis Inc 61
Novartis AG 61
Novogen Ltd 62
OGD2 Pharma SAS 62
Pfizer Inc 63
Phylogica Ltd 63
Progenics Pharmaceuticals Inc 64
Recombio SL 64
Ribomic Inc 65
Sapience Therapeutics Inc 65
Sareum Holdings Plc 65
Sierra Oncology Inc 66
Sorrento Therapeutics Inc 66
Syros Pharmaceuticals Inc 67
Tiltan Pharma Ltd 67
Neuroblastoma - Drug Profiles 69
1-B7 - Drug Profile 69
31-F9 - Drug Profile 71
9-ING41 - Drug Profile 72
abexinostat hydrochloride - Drug Profile 74
ABTL-0812 - Drug Profile 77
ACY-1035 - Drug Profile 80
ACY-957 - Drug Profile 81
afatinib dimaleate - Drug Profile 84
ALKCAR-15 - Drug Profile 99
ALKCAR-48 - Drug Profile 100
ALKCAR-53 - Drug Profile 101
ALKCAR-58 - Drug Profile 102
AMB-8LK - Drug Profile 103
AMXT-1501 + eflornithine hydrochloride - Drug Profile 104
APN-301 - Drug Profile 106
AT-69 - Drug Profile 108
BACPT-DP - Drug Profile 109
bevacizumab - Drug Profile 110
BGA-002 - Drug Profile 122
Bispecific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile 123
BL-8040 - Drug Profile 124
BPX-701 - Drug Profile 137
BXQ-350 - Drug Profile 139
CBL-0137 - Drug Profile 141
CCT-244747 - Drug Profile 145
CCT-68127 - Drug Profile 147
CEB-01 - Drug Profile 148
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 149
Cellular Immunotherapy for Neuroblastoma - Drug Profile 151
Cellular Immunotherapy for Neuroblastoma - Drug Profile 152
Cellular Immunotherapy for Oncology - Drug Profile 153
Cellular Immunotherapy to Target CD3 and GD2 for Neuroblastoma - Drug Profile 155
Cellular Immunotherapy to Target GD2 and CD56 for Solid Tumors - Drug Profile 156
Cellular Immunotherapy to Target GD2 for Melanoma and Neuroblastoma - Drug Profile 157
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 158
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 159
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 160
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 161
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 162
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 163
Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 164
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 165
Celyvir - Drug Profile 166
ceritinib - Drug Profile 167
CG-1521 - Drug Profile 174
CMD-501 - Drug Profile 175
crizotinib - Drug Profile 176
CYC-065 - Drug Profile 183
dactolisib tosylate - Drug Profile 187
danusertib - Drug Profile 189
dinutuximab beta - Drug Profile 191
DS-1647 - Drug Profile 194
Edotreotide Labeled Yttrium 90 - Drug Profile 195
eflornithine - Drug Profile 197
eh-8B6 - Drug Profile 199
enoblituzumab - Drug Profile 200
ensartinib - Drug Profile 203
entrectinib - Drug Profile 206
fimepinostat - Drug Profile 215
FSEC - Drug Profile 220
Gene Therapy to Activate GAS1 for Oncology - Drug Profile 221
GSK-525762 - Drug Profile 222
HSV-1716 - Drug Profile 224
ICA-1 - Drug Profile 228
Immuncell-LC - Drug Profile 229
ImmuneFx - Drug Profile 231
iobenguane sulfate I 131 - Drug Profile 232
ipilimumab + nivolumab - Drug Profile 236
irinotecan hydrochloride - Drug Profile 246
irinotecan hydrochloride + TBio-02 - Drug Profile 258
JCAR-023 - Drug Profile 260
Kid EDV - Drug Profile 261
KOS-1803 - Drug Profile 262
KTN-0125TEI - Drug Profile 264
larotrectinib - Drug Profile 265
lorlatinib - Drug Profile 272
lutetium Lu 177 dotatate - Drug Profile 275
M-606 - Drug Profile 282
M-7085 - Drug Profile 283
Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile 284
Monoclonal Antibody Conjugate to Target CD56 for Neuroblastoma - Drug Profile 286
Monoclonal Antibody Conjugates to Target Glypican-2 for Neuroblastoma - Drug Profile 287
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 288
Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile 289
MPTEM-1ADC - Drug Profile 291
NCE-001 - Drug Profile 292
nifurtimox - Drug Profile 293
OGD-201 - Drug Profile 294
olaparib - Drug Profile 295
Oncolytic Virus for Neuroblastoma - Drug Profile 309
Oncolytic Virus for Neuroblastoma - Drug Profile 310
Oncolytic Virus to Activate TIMP3 for Neuroblastoma and Malignant Peripheral Nerve Sheath Tumor - Drug Profile 311
ORP-008 - Drug Profile 312
paclitaxel albumin bound - Drug Profile 313
pazopanib hydrochloride - Drug Profile 326
pembrolizumab - Drug Profile 335
Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile 397
racotumomab - Drug Profile 398
RBM-001 - Drug Profile 400
ribociclib succinate - Drug Profile 401
RNAi Oligonucleotides for Neuroblastoma - Drug Profile 409
RSF-701 - Drug Profile 411
SAR-020106 - Drug Profile 412
SAR-4 - Drug Profile 414
selumetinib sulfate - Drug Profile 416
SF-1126 - Drug Profile 424
SF-2523 - Drug Profile 427
Small Molecules 3 for Oncology - Drug Profile 429
Small Molecules to Inhibit ALK for Oncology - Drug Profile 430
Soluble Beta Glucan - Drug Profile 431
SRA-737 - Drug Profile 434
ST-36 - Drug Profile 438
SY-1365 - Drug Profile 439
Synthetic Peptide to Inhibit C-Myc for Oncology - Drug Profile 443
Synthetic Peptide to Inhibit N-Myc for Oncology - Drug Profile 444
taurolidine - Drug Profile 445
tazemetostat - Drug Profile 446
TL-118 - Drug Profile 458
TR-100 - Drug Profile 460
TRBS-07 - Drug Profile 461
Trilexium - Drug Profile 462
Vaccine for Neuroblastoma - Drug Profile 464
Vaccine for Neuroblastoma - Drug Profile 466
Vaccine for Neuroblastoma - Drug Profile 467
Vaccine to Target GD2 and GD3 for Neuroblastoma - Drug Profile 468
Vaccine to Target WT1 for Oncology - Drug Profile 469
vemurafenib - Drug Profile 470
VIMO-001 - Drug Profile 478
Neuroblastoma - Dormant Projects 479
Neuroblastoma - Discontinued Products 482
Neuroblastoma - Product Development Milestones 483
Featured News & Press Releases 483
Appendix 496
Methodology 496
Coverage 496
Secondary Research 496
Primary Research 496
Expert Panel Validation 496
Contact Us 496
Disclaimer 497

List of Tables
Number of Products under Development for Neuroblastoma, H2 2017 20
Number of Products under Development by Companies, H2 2017 22
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 23
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 24
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 25
Number of Products under Development by Universities/Institutes, H2 2017 26
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 28
Products under Development by Companies, H2 2017 29
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 30
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 31
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 32
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 33
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 34
Products under Development by Universities/Institutes, H2 2017 35
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 36
Number of Products by Stage and Target, H2 2017 38
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 39
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 40
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 41
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 42
Number of Products by Stage and Mechanism of Action, H2 2017 44
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 45
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 46
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 47
Number of Products by Stage and Route of Administration, H2 2017 49
Number of Products by Stage and Molecule Type, H2 2017 51
Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H2 2017 52
Neuroblastoma - Pipeline by Actuate Therapeutics Inc, H2 2017 52
Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H2 2017 53
Neuroblastoma - Pipeline by Alissa Pharma, H2 2017 53
Neuroblastoma - Pipeline by Ampio Pharmaceuticals Inc, H2 2017 53
Neuroblastoma - Pipeline by APAvadis Biotechnologies Srl, H2 2017 54
Neuroblastoma - Pipeline by APEIRON Biologics AG, H2 2017 54
Neuroblastoma - Pipeline by AstraZeneca Plc, H2 2017 55
Neuroblastoma - Pipeline by Autolus Ltd, H2 2017 55
Neuroblastoma - Pipeline by Bayer AG, H2 2017 56
Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017 56
Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H2 2017 57
Neuroblastoma - Pipeline by BioLineRx Ltd, H2 2017 57
Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H2 2017 57
Neuroblastoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017 58
Neuroblastoma - Pipeline by Bristol-Myers Squibb Co, H2 2017 58
Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017 59
Neuroblastoma - Pipeline by Cebiotex SL, H2 2017 59
Neuroblastoma - Pipeline by Celgene Corp, H2 2017 60
Neuroblastoma - Pipeline by Celldex Therapeutics Inc, H2 2017 60
Neuroblastoma - Pipeline by Cielo Therapeutics Inc, H2 2017 61
Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H2 2017 61
Neuroblastoma - Pipeline by CorMedix Inc, H2 2017 62
Neuroblastoma - Pipeline by Curis Inc, H2 2017 62
Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 63
Neuroblastoma - Pipeline by DEKK-TEC Inc, H2 2017 63
Neuroblastoma - Pipeline by EnGeneIC Ltd, H2 2017 63
Neuroblastoma - Pipeline by Epizyme Inc, H2 2017 64
Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H2 2017 64
Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 65
Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H2 2017 65
Neuroblastoma - Pipeline by Green Cross Cell Corp, H2 2017 66
Neuroblastoma - Pipeline by Ignyta Inc, H2 2017 66
Neuroblastoma - Pipeline by Ipsen SA, H2 2017 67
Neuroblastoma - Pipeline by Juno Therapeutics Inc, H2 2017 67
Neuroblastoma - Pipeline by Lindis Biotech GmbH, H2 2017 67
Neuroblastoma - Pipeline by Loxo Oncology Inc, H2 2017 68
Neuroblastoma - Pipeline by MabVax Therapeutics Holdings Inc, H2 2017 68
Neuroblastoma - Pipeline by MacroGenics Inc, H2 2017 69
Neuroblastoma - Pipeline by MediaPharma SRL, H2 2017 69
Neuroblastoma - Pipeline by Merck & Co Inc, H2 2017 70
Neuroblastoma - Pipeline by Morphogenesis Inc, H2 2017 70
Neuroblastoma - Pipeline by Novartis AG, H2 2017 71
Neuroblastoma - Pipeline by Novogen Ltd, H2 2017 71
Neuroblastoma - Pipeline by OGD2 Pharma SAS, H2 2017 72
Neuroblastoma - Pipeline by Pfizer Inc, H2 2017 72
Neuroblastoma - Pipeline by Phylogica Ltd, H2 2017 73
Neuroblastoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2017 73
Neuroblastoma - Pipeline by Recombio SL, H2 2017 74
Neuroblastoma - Pipeline by Ribomic Inc, H2 2017 74
Neuroblastoma - Pipeline by Sapience Therapeutics Inc, H2 2017 74
Neuroblastoma - Pipeline by Sareum Holdings Plc, H2 2017 75
Neuroblastoma - Pipeline by Sierra Oncology Inc, H2 2017 75
Neuroblastoma - Pipeline by Sorrento Therapeutics Inc, H2 2017 76
Neuroblastoma - Pipeline by Syros Pharmaceuticals Inc, H2 2017 76
Neuroblastoma - Pipeline by Tiltan Pharma Ltd, H2 2017 77
Neuroblastoma - Dormant Projects, H2 2017 488
Neuroblastoma - Dormant Projects, H2 2017 (Contd..1), H2 2017 489
Neuroblastoma - Dormant Projects, H2 2017 (Contd..2), H2 2017 490
Neuroblastoma - Discontinued Products, H2 2017 491

List of Figures
Number of Products under Development for Neuroblastoma, H2 2017 20
Number of Products under Development by Companies, H2 2017 21
Number of Products under Development by Universities/Institutes, H2 2017 26
Number of Products by Top 10 Targets, H2 2017 37
Number of Products by Stage and Top 10 Targets, H2 2017 37
Number of Products by Top 10 Mechanism of Actions, H2 2017 43
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 43
Number of Products by Routes of Administration, H2 2017 48
Number of Products by Stage and Routes of Administration, H2 2017 48
Number of Products by Top 10 Molecule Types, H2 2017 50
Number of Products by Stage and Top 10 Molecule Types, H2 2017 50

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *